By Tom Kerr, CFA
NASDAQ: CTSO
READ THE FULL CTSO RESEARCH REPORT
2nd Quarter 2026 Financial Results
On August 6, 2026, CytoSorbents (NASDAQ: CTSO) released 2nd quarter financial and operating results. Revenue remained stable at $9.6 million in the 2nd quarter, while profitability continued to improve as the company expanded gross margin to 73%, up from 69% in the prior quarter and 71% a year earlier. The higher margin, combined with disciplined cost management, drove a 27% reduction in operating loss to ($2.6) million, demonstrating continued progress toward improving operating leverage despite a flat revenue environment.
Reported results were affected by non-cash foreign currency translation losses, resulting in a net loss of ($4.4) million, or ($0.07) per share, compared with net income of $1.9 million or $0.03 per share in the prior year period. Excluding these non-cash foreign exchange impacts and stock-based compensation, core profitability improved meaningfully, with adjusted net loss narrowing 22% to ($2.8) million or ($0.05) per share and adjusted EBITDA loss improved 38% to ($1.6) million.
Total cash and equivalents (including restricted cash) was approximately $5.9 million on June 30, 2026, compared to $6.3 million as of March 31, 2026. Total cash burn in the 2nd quarter was reduced to $0.4 million, inclusive of approximately $0.2 million in restructuring-related payments. Going forward, we expect the quarterly cash burn for the rest of the year to be approximately $200,000 per quarter.
Revenue in the quarter was driven by strong growth across distributor and strategic partner channels, as well as direct sales outside of Germany, and was partially offset by weaker sales in Germany following the transition to a more focused sales organization. Management indicated that sales productivity and execution in Germany have improved and plans to hire an additional three to five sales representatives through early 2027 to restore full market coverage and improve revenue growth.
The company also continued to improve operational efficiency during the quarter, with gross margin expanding to 73%, operating loss declining 27%, and adjusted EBITDA loss improving 38%. Operating cash burn, excluding restructuring payments, was reduced to approximately $200,000, reflecting manufacturing optimization, improved working capital management, stronger commercial execution, and tighter cost controls. Based on these trends, the company believes it remains on track to achieve operating cash flow breakeven during the 2nd half of 2026.
Valuation and Estimates
Based on 2nd quarter 2026 results and management commentary, we adjust our full year 2026 revenue estimate to $38.1 million and adjust our 2026 non-GAAP loss per share to ($0.22). We believe 2027 revenues can reach over $40.0 million without the commercialization of DrugSorb-ATR.
In the 4th quarter of 2025, the company implemented a strategic workforce and cost reduction program which reduced headcount by 10% while also lowering expenses and realigning operating and production spend. According to the company’s recent earnings call, it continues to expect to achieve breakeven in the second half of 2026. We did see the results of these actions in the 2nd quarter, as the going forward burn rate was reduced to approximately $200,000 per quarter.
We adjust our price target to $4.00 per share due to the uncertainty of the timing of the DrugSorb-ATR submission and subsequent approval (if approved) in 2027.
Four Value Drivers
In the press release, management outlined four largely independent business drivers over the next 6-18 months that are expected to increase shareholder value and provide meaningful long-term growth.
1. Achieving Operating Cash Flow Breakeven
The first value driver is reducing financial risk by achieving sustainable operating cash flow breakeven. Over the past year, the company has focused relentlessly on improving the economics of the overall business. Product gross margin improved to 73% during the 2nd quarter through manufacturing optimization, improved sourcing, and production efficiencies. The company also lowered its cash burn through improved commercial execution, collections, and working capital management while continuing to streamline the total organization. Since September 2025, there has been a 23% workforce reduction, which has created a leaner and more focused company. This is an important milestone because it fundamentally changes the company’s historical financial profile. Every dollar of operating cash burn eliminated reduces future financing needs, strengthens the balance sheet, increases strategic flexibility, and allows a greater proportion of future growth to accrue to shareholders.
2. Returning the CytoSorb Business to Sustainable, Profitable Growth
The second value driver is returning the core CytoSorb business to sustainable, profitable growth. Underlying business trends remained mostly positive during the 2nd quarter, with 16% growth in distributor and strategic partner sales and 9% growth in direct sales outside Germany. This was partially offset by a 24% decline in Germany following the company's sales force restructuring. Management expects Germany to return to growth as territory coverage is restored through planned sales-related hiring. Customer adoption of the company's PuriFi® pump platform and HotSwap® technology continued to increase, supporting earlier treatment, improved therapy delivery, and more consistent utilization of CytoSorb products. These, and other initiatives, particularly the operational investments and commercial restructuring completed over the past year, have positioned CytoSorbents for greater sales effectiveness that can strengthen both clinical adoption and long-term profitable growth of the franchise.
3. Opening the U.S. Market Through DrugSorb-ATR
The third value driver is obtaining FDA marketing approval for DrugSorb-ATR and opening what is likely the company’s most important long-term growth opportunity. DrugSorb-ATR targets a significant unmet need in cardiac surgery by removing commonly prescribed blood thinners during cardiopulmonary bypass for patients requiring urgent procedures. Supported by positive STAR-T trial results and expanding real-world evidence for Brilinta®, Eliquis®, and Xarelto®, the company believes the technology has strong global commercial potential. In the U.S. and Canada alone, the initial addressable market is estimated at $500 million to $1 billion, with additional expansion opportunities across other surgical indications.
The company has two FDA pre-submission meetings scheduled in August to advance its Brilinta® and direct oral anticoagulant (DOAC) programs. Management expects these discussions to clarify the remaining requirements for De Novo submissions, including a planned Brilinta® filing in early 2027 supported by expanded real-world clinical data. Regulatory approval would establish a second commercial franchise alongside the international CytoSorb business, expand access to the U.S. market, and support higher margins and long-term growth.
In addition, the findings of an important comparative real-world analysis entitled “Intraoperative ticagrelor removal to reduce bleeding after urgent CABG: Matched comparison of patient-level observational data” will be presented at the upcoming European Society of Cardiology’s ESC 2026 conference (August 28-31, 2026) in Munich, Germany. These data, released at the world’s largest cardiovascular conference, are expected to preview real-world evidence that will be provided to the FDA in a new De Novo submission, giving investors an opportunity for the first time to assess for themselves the strength of these new data and how it may impact the chances of a successful second De Novo submission.
4. Unlocking the Strategic Value of HemoDefend-BGA
The fourth value driver is realizing the strategic value of HemoDefend-BGA, which is a technology that is not likely reflected in today’s valuation. HemoDefend-BGA is a sophisticated blood filter designed to remove anti-A and anti-B antibodies from plasma and platelet products, enabling the production of ‘universal’ blood products that can be transfused regardless of recipient blood type. This can be done without electricity, capital equipment, or complex processing and was supported by approximately $16 million in non-dilutive government funding.
This product has the potential to transform blood product management by simplifying inventories, reducing waste and costs, and improving access to critical blood products. Validated with support from leading blood centers, the technology could enable universal plasma and platelet products, reducing complexity in hospital blood banks and expanding the availability of life-saving transfusions in emergency settings, including ambulances, first responders, and military applications. Put simply, imagine the simplification and cost savings to hospital blood banks from currently maintaining 4 types of plasma (A, B, AB, O) and 4 types of platelets to just 1 universal plasma and 1 universal platelet product in the future.
Over the past year, the company completed product development and received constructive FDA feedback in July 2026 regarding the anticipated clinical pathway. The company also continues to engage with U.S. government agencies regarding potential non-dilutive funding opportunities to support future clinical development. HemoDefend-BGA could represent a valuable strategic asset for CytoSorbents with multiple potential pathways to create shareholder value, including commercial partnerships, licensing opportunities, government funding, or other strategic alternatives.
We view HemoDefend-BGA as an exciting wild card for investors, as the program has clearly made significant progress since our last update. The importance of universal blood products, such as plasma and platelets that can be administered to patients regardless of blood type, has become increasingly visible amid ongoing global conflicts. The company noted that the first FDA approval of freeze-dried plasma technology occurred less than a month ago. When potentially combined with the low-titer “universal” plasma produced by HemoDefend-BGA, this technology could create “freeze-dried universal plasma.” This would represent the “holy grail” of plasma products: a solution that could be stored and stockpiled without refrigeration, then reconstituted and administered on demand simply by adding water. We believe this asset has significant strategic potential for the company and could emerge as a meaningful value driver for investors.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.